Ποια είναι η κεφαλαιοποίηση αγοράς για BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (BML)

Η κεφαλαιοποίηση αγοράς για BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (BML) είναι $81.94M

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (BML) Τιμή και Κεφαλαιοποίηση Αγοράς

Q: Ποια είναι η τιμή για BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (BML)

Η τιμή για BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (BML) είναι $1.32

Established in 1944 and headquartered in Lublin, Poland, BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. is a biotechnology enterprise engaged in the manufacturing and distribution of pharmaceutical products, medical devices, and laboratory reagents throughout Poland. The company's range of prescription medications includes Distreptaza, utilized in gynecology for addressing chronic inflammatory conditions of the uterine appendages and hemorrhoids. Onko BCG 50 is prescribed for the treatment of superficial (non-muscle invasive) bladder tumors. For passive immunity against hepatitis B, they provide GAMMA anty HBs 200. Additionally, GAMMA anty-D 50 and GAMMA anty-D 150 are Anti D (Rho) immunoglobulin formulations crucial for preventing hemolytic disease in newborns. BioTrombina 400 offers localized control for significant bleeding, and the Anti-Tuberculosis Vaccine BCG 10 is integral to tuberculosis prevention efforts. Beyond pharmaceuticals, BIOMED-LUBLIN supplies a variety of medical and laboratory-grade items. These encompass Ram blood for laboratory applications; Stonebrink medium for the diagnosis of bovine Mycobacterium tuberculosis; and specific Löwenstein-Jensen media, including one adapted for assessing Mycobacterium tuberculosis's drug susceptibility and another containing glycerol for its identification. Their offerings also extend to Ox Thrombin for in-vitro diagnostics and lyophilized preparations, alongside rabbit plasma. Furthermore, the company offers an extensive catalog of reagents. This includes various sera (horse, bovine, calf), essential solutions like trypsin, PBS fluid, Hanks fluid, and Parker's fluid, as well as diverse culture media such as Eagle 1959, RPMI 1640, and Ogawa medium. Completing their reagent portfolio are pseudo cholinesterase, Ox fibrinogen, and rabbit complements.

Η τιμή για BML	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$83,703.12 $81.94M	NVDA	$5.211T	+6,359,890.79%
$73,028.19 $81.94M	AAPL	$4.547T	+5,548,780.38%
$66,856.18 $81.94M	GOOG	$4.162T	+5,079,814.58%
$57,706.10 $81.94M	MSFT	$3.593T	+4,384,566.75%
$44,857.81 $81.94M	AMZN	$2.793T	+3,408,318.81%

Η τιμή για BML

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$83,703.12 $81.94M